We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Doctaly is  the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go: Expired investment: £807,580
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £907,540
Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £488,450
Field&flower are a trusted retailer of ethical meat, fish and cheese. They provide grass fed, free range meat boxes to over 4500 active subscription customers. They were profitable in 16/17 with a revenue of £2.7m and are now looking to expand and become a major online food retailer.
days to go: Expired investment: £877,030
DABBOUS is a highly successful, Michelin starred, modern fine-dining restaurant and bar in central London. Opened in January 2012 by Ollie Dabbous and Oskar Kinberg, DABBOUS offers innovative style and creative interpretation of modern European cuisine in an industrial setting.  
days to go: Expired investment: £3,124,165
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph